Pharmacokinetics, pharmacodynamics, and comparative bioavailability of single, oral 2-mg doses of dexamethasone liquid and tablet formulations: A randomized, controlled, crossover study in healthy adult volunteers

Clinical Therapeutics

Volumn 33, Issue 11, 2011, Pages 1831-1841

  Queckenberg, Christian ^a   Wachall, Bertil ^b   Erlinghagen, Valerie ^a   Di Gion, Paola ^a   Tomalik Scharte, Dorota ^a   Tawab, Mona ^c   Gerbeth, Kathleen ^c   Fuhr, Uwe ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b InfectoPharm Arzneimittel und Consilium GmbH   (Germany)

^c ABDA Bundesvereinigung Deutscher Apothekerverbande   (Germany)

Author keywords

Bioequivalence; Cortisol; Dexamethasone; Pharmacodynamics; Pharmacokinetics

Indexed keywords

DEXAMETHASONE; HYDROCORTISONE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CONFIDENCE INTERVAL; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-SECTIONAL STUDIES; DEXAMETHASONE; DOSAGE FORMS; FEMALE; HUMANS; MALE; SPECTROPHOTOMETRY, ULTRAVIOLET; TABLETS;

EID: 82855179427     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.10.006     Document Type: Article

References (29)

1. Harahap Y., Sasongko L., Prasaja B., et al. Comparative bioavailability of two dexamethasone tablet formulations in Indonesian healthy volunteers. Arzneimittel-Forschung 2009, 59:191-194.
2. Kim J.H., Kim T.W., Ryu M.H., et al. A randomised crossover study comparing ramosetron plus dexamethasone with ramosetron alone in the prevention of cisplatin-induced emesis. Clin Drug Invest 2005, 25:191-197.
3. Yang L., Panetta J.C., Cai X., et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 2008, 26:1932-1939.
4. Guthrie S.K., Heidt M., Pande A., et al. A longitudinal evaluation of dexamethasone pharmacokinetics in depressed patients and normal controls. J Clin Psychopharmacol 1992, 12:191-196.
5. O'Sullivan B.T., Cutler D.J., Hunt G.E., et al. Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects. Biol Psychiatry 1997, 41:574-584.
6. Findling J.W., Raff H., Aron D.C. The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome. J Clin Endocrinol Metab 2004, 89:1222-1226.
7. Sahin M., Kebapcilar L., Taslipinar A., et al. Comparison of 1 mg and 2 mg overnight dexamethasone suppression tests for the screening of Cushing's syndrome in obese patients. Intern Med 2009, 48:33-39.
8. Bjornson C.L., Klassen T.P., Williamson J., et al. A randomized trial of a single dose of oral dexamethasone for mild croup. N Engl J Med 2004, 351:1306-1313.
9. Chub-Uppakarn S., Sangsupawanich P. A randomized comparison of dexamethasone 0.15 mg/kg versus 0.6 mg/kg for the treatment of moderate to severe croup. Int J Pediatr Otorhinolaryngol 2007, 71:473-477.
10. Luria J.W., Gonzalez-del-Rey J.A., DiGiulio G.A., et al. Effectiveness of oral or nebulized dexamethasone for children with mild croup. Arch Pediatr Adolesc Med 2001, 155:1340-1345.
11. Toth G.G., Kloosterman C., Uges D.R., Jonkman M.F. Pharmacokinetics of high-dose oral and intravenous dexamethasone. Ther Drug Monit 1999, 21:532-535.
12. Hutto C.J., Bratton T.H. Palatability and cost comparison of five liquid corticosteroid formulations. J Pediatr Oncol Nurs 1999, 16:74-77.
13. Richter O., Ern B., Reinhardt D., Becker B. Pharmacokinetics of dexamethasone in children. Pediatr Pharmacol (New York) 1983, 3:329-337.
14. Liebermann P., Kemp S.F., Oppenheimer J., et al. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol 2005, 115(3 Suppl 2):S483-S523. Joint Task Force on Practice Parameters.
15. Brophy T.R., McCafferty J., Tyrer J.H., Eadie M.J. Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients. Eur J Clin Pharmacol 1983, 24:103-108.
16. Czock D., Keller F., Rasche F.M., Haussler U. Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients. Eur J Clin Pharmacol 1983, 24:103-108.
17. Shah V.P., Midha K.K., Dighe S., et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet 1991, 16:249-255.
18. CPMP Guideline on the Investigation of Bioequivalence (CPMP/QWP/EWP/1401/98 Rev. 1) as of January 20, 2010 European Medicines Agency, Accessed October 25, 2011. http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf.
19. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations, March 2003 US Food and Drug Administration, Accessed October 17, 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf.
20. Compton P., Ling W., Moody D., Chiang N. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug Alcohol Depend 2006, 82:25-31.
21. Saano V., Paronen P., Peura P., Vidgren M. Relative pharmacokinetics of three oral 400 mg ibuprofen dosage forms in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1991, 29:381-385.
22. Queckenberg C., Fuhr U. Influence of posture on pharmacokinetics. Eur J Clin Pharmacol 2009, 65:109-119.
23. Loew D., Schuster O., Graul E.H. Dose-dependent pharmacokinetics of dexamethasone. Eur J Clin Pharmacol 1986, 30:225-230.
24. Kasim N.A., Whitehouse M., Ramachandran C., et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004, 1:85-96.
25. Rinaki E., Valsami G., Macheras P. Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. Pharm Res 2003, 20:1917-1925.
26. Ritchie J.C., Belkin B.M., Krishnan K.R., et al. Plasma dexamethasone concentrations and the dexamethasone suppression test. Biol Psychiatry 1990, 27:159-173.
27. Guthrie S. The impact of dexamethasone pharmacokinetics on the DST: a review. Psychopharmacol Bull 1991, 27:565-576.
28. Gilpin H., Whitcomb D., Cho K. Atypical evening cortisol profile induces visual recognition memory deficit in healthy human subjects. Mol Brain 2008, 1:4.
29. Edwards S., Clow A., Evans P., Hucklebridge F. Exploration of the awakening cortisol response in relation to diurnal cortisol secretory activity. Life Sci 2001, 68:2093-2103.